EASL clinical practice guidelines: Autoimmune hepatitis

Journal of Hepatology

Volumn 63, Issue 4, 2015, Pages 971-1004

  Lohse, Ansgar W ^b   Chazouillères, Olivier ^b   Dalekos, George ^b   Drenth, Joost ^b   Heneghan, Michael ^b   Hofer, Harald ^b   Lammert, Frank ^b   Lenzi, Marco ^b  

^a EASL Office   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL LIVER DISEASE; AUTOIMMUNE HEPATITIS; CELIAC DISEASE; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; CLINICAL FEATURE; DISEASE ACTIVITY; FOLLOW UP; GENETIC PREDISPOSITION; GRANULOMATOUS HEPATITIS; HEMOCHROMATOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRACTICE GUIDELINE; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TOXIC HEPATITIS; VIRUS HEPATITIS; WILSON DISEASE; DISEASE MANAGEMENT; GASTROENTEROLOGY; HEPATITIS, AUTOIMMUNE; STANDARDS; UNITED STATES;

ANTIVIRUS AGENT;

ANTIVIRAL AGENTS; DISEASE MANAGEMENT; GASTROENTEROLOGY; HEPATITIS, AUTOIMMUNE; HUMANS; UNITED STATES;

EID: 84941943275     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2015.06.030     Document Type: Article

References (327)

1. T.M. Shaneyfelt, M.F. Mayo-Smith, and J. Rothwangl Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature JAMA 281 1999 1900 1905
2. E.L. Krawitt Autoimmune hepatitis N Engl J Med 354 2006 54 66
3. A.W. Lohse, and G. Mieli-Vergani Autoimmune hepatitis J Hepatol 55 2011 171 182
4. K. Zachou, P. Muratori, G.K. Koukoulis, A. Granito, N. Gatselis, A. Fabbri, and et al. Review article: autoimmune hepatitis - Current management and challenges Aliment Pharmacol Ther 38 2013 887 913
5. M.P. Manns, A.W. Lohse, and D. Vergani Autoimmune hepatitis - Update 2015 J Hepatol 62 2015 S1 S186
6. K.M. Boberg, E. Aadland, J. Jahnsen, N. Raknerud, M. Stiris, and H. Bell Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population Scand J Gastroenterol 33 1998 99 9103
7. J.J. Feld, and E.J. Heathcote Epidemiology of autoimmune liver disease J Gastroenterol Hepatol 18 2003 1118 1128
8. M. Werner, H. Prytz, B. Ohlsson, S. Almer, E. Bjornsson, A. Bergquist, and et al. Epidemiology and the initial presentation of autoimmune hepatitis in Sweden: a nationwide study Scand J Gastroenterol 43 2008 1232 1240
9. J.H. Ngu, K. Bechly, B.A. Chapman, M.J. Burt, M.L. Barclay, R.B. Gearry, and et al. Population-based epidemiology study of autoimmune hepatitis: a disease of older women? J Gastroenterol Hepatol 25 2010 1681 1686
10. J.-S. Delgado, A. Vodonos, S. Malnick, O. Kriger, R. Wilkof-Segev, B. Delgado, and et al. Autoimmune hepatitis in southern Israel: a 15-year multicenter study J Dig Dis 14 2013 611 618
11. N.M.F. van Gerven, B.J. Verwer, B.I. Witte, K.J. van Erpecum, H.R. van Buuren, I. Maijers, and et al. Epidemiology and clinical characteristics of autoimmune hepatitis in the Netherlands Scand J Gastroenterol 49 2014 1245 1254
12. K.J. Hurlburt, B.J. McMahon, H. Deubner, B. Hsu-Trawinski, J.L. Williams, and K.V. Kowdley Prevalence of autoimmune liver disease in Alaska Natives Am J Gastroenterol 97 2002 2402 2407
13. L. Grønbæk, H. Vilstrup, and P. Jepsen Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study J Hepatol 60 2014 612 617
14. G.Y. Minuk, S. Liu, K. Kaita, S. Wong, E. Renner, J. Rempel, and et al. Autoimmune hepatitis in a North American Aboriginal/First Nations population Can J Gastroenterol 22 2008 829 834
15. S. Verma, M. Torbenson, and P.J. Thuluvath The impact of ethnicity on the natural history of autoimmune hepatitis Hepatology 46 2007 1828 1835
16. K.N. Lim, R.L. Casanova, T.D. Boyer, and C.J. Bruno Autoimmune hepatitis in African Americans: presenting features and response to therapy Am J Gastroenterol 96 2001 3390 3394
17. L. Munoz-Espinosa, G. Alarcon, A. Mercado-Moreira, P. Cordero, E. Caballero, V. Avalos, and et al. Performance of the international classifications criteria for autoimmune hepatitis diagnosis in Mexican patients Autoimmunity 44 2011 543 548
18. R.J. Wong, R. Gish, T. Frederick, N. Bzowej, and C. Frenette The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis J Clin Gastroenterol 46 2012 155 161
19. C. Levy, J. Naik, C. Giordano, A. Mandalia, C. O'Brien, K.R. Bhamidimarri, and et al. Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics Clin Gastroenterol Hepatol 12 2014 1398 1405
20. T. Zolfino, M.A. Heneghan, S. Norris, P.M. Harrison, B.C. Portmann, and I.G. McFarlane Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin Gut 50 2002 713 717
21. A.J. Czaja Autoimmune hepatitis in diverse ethnic populations and geographical regions Expert Rev Gastroenterol Hepatol 7 2013 365 385
22. Waldenström J. Leber Blutproteine und Nahrungseiweiss Deutsch Z Verdau Stoffwechselkr 15 1950 113 119
23. H.G. Kunkel, E.H. Ahrens Jr., W.J. Eigenmenger, A.M. Bougiovanni, and R.J. Slater Extreme hypergammaglobulinemia in young women with liver disease of unknown etiology J Clin Invest 30 1951 654 [abstract]
24. D.C. Cowling, I.R. Mackay, and L.I. Taft Lupoid hepatitis Lancet 271 1956 1323 1326
25. I.R. Mackay, S. Weiden, and J. Hasker Autoimmune hepatitis Ann N Y Acad Sci 124 1965 767 780
26. P.J. Johnson, and I.G. McFarlane Meeting report: International Autoimmune Hepatitis Group Hepatology 18 1993 998 1005
27. F. Alvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, E.L. Cancado, and et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis J Hepatol 31 1999 929 938
28. E.M. Hennes, M. Zeniya, A.J. Czaja, A. Pares, G.N. Dalekos, E.L. Krawitt, and et al. Simplified criteria for the diagnosis of autoimmune hepatitis Hepatology 48 2008 169 176
29. P. Muratori, A. Granito, C. Quarneti, S. Ferri, R. Menichella, F. Cassani, and et al. Autoimmune hepatitis in Italy: the Bologna experience J Hepatol 50 2009 1210 1218
30. C. Schramm, S. Kanzler, K.H. zum Buschenfelde, P.R. Galle, and A.W. Lohse Autoimmune hepatitis in the elderly Am J Gastroenterol 96 2001 1587 1591
31. M. Peng, Y. Li, M. Zhang, Y. Jiang, Y. Xu, Y. Tian, and et al. Clinical features in different age groups of patients with autoimmune hepatitis Exp Ther Med 7 2014 145 148
32. J. Chen, G.D. Eslick, and M. Weltman Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly Aliment Pharmacol Ther 39 2014 117 124
33. M. Abe, T. Mashiba, M. Zeniya, K. Yamamoto, M. Onji, H. Tsubouchi, and et al. Present status of autoimmune hepatitis in Japan: a nationwide survey J Gastroenterol 46 2011 1136 1141
34. M.P. Manns, A.J. Czaja, J.D. Gorham, E.L. Krawitt, G. Mieli-Vergani, D. Vergani, and et al. Diagnosis and management of autoimmune hepatitis Hepatology 51 2010 2193 2213
35. T. Al-Chalabi, S. Boccato, B.C. Portmann, I.G. McFarlane, and M.A. Heneghan Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre J Hepatol 45 2006 575 583
36. C. Schramm, I. Wahl, C. Weiler-Normann, K. Voigt, C. Wiegard, C. Glaubke, and et al. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis J Hepatol 60 2014 618 624
37. R.T. Stravitz, J.H. Lefkowitch, R.J. Fontana, M.E. Gershwin, P.S. Leung, R.K. Sterling, and et al. Autoimmune acute liver failure: proposed clinical and histological criteria Hepatology 53 2011 517 526
38. H. Takahashi, and M. Zeniya Acute presentation of autoimmune hepatitis: Does it exist? A published work review Hepatol Res 41 2011 498 504
39. R. Ferrari, G. Pappas, D. Agostinelli, P. Muratori, L. Muratori, M. Lenzi, and et al. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type QJM 97 2004 407 412
40. D. Gleeson, and M.A. Heneghan British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis Gut 60 2011 1611 1629
41. A.J. Czaja Autoimmune hepatitis in special patient populations Best Pract Res Clin Gastroenterol 25 2011 689 700
42. Y. Miyake, Y. Iwasaki, R. Terada, T. Onishi, R. Okamoto, N. Sakai, and et al. Clinical characteristics of fulminant-type autoimmune hepatitis: an analysis of eleven cases Aliment Pharmacol Ther 23 2006 1347 1353
43. J. Karkhanis, E.C. Verna, M.S. Chang, R.T. Stravitz, M. Schilsky, W.M. Lee, and et al. Steroid use in acute liver failure Hepatology 59 2014 612 621
44. J.J. Feld, H. Dinh, T. Arenovich, V.A. Marcus, I.R. Wanless, and E.J. Heathcote Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome Hepatology 42 2005 53 62
45. K. Zachou, N. Gatselis, G. Papadamou, E.I. Rigopoulou, and G.N. Dalekos Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients J Hepatol 55 2011 636 646
46. G. Landeira, S. Morise, E. Fassio, M. Ramonet, E. Alvarez, P. Caglio, and et al. Effect of cirrhosis at baseline on the outcome of type 1 autoimmune hepatitis Ann Hepatol 11 2012 100 106
47. J.H. Ngu, R.B. Gearry, C.M. Frampton, and C.A. Stedman Predictors of poor outcome in patients with autoimmune hepatitis: a population-based study Hepatology 57 2013 2399 2406
48. M. Manns, G. Gerken, A. Kyriatsoulis, M. Staritz, and K.H. Meyer zum Büschenfelde Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen Lancet 1 1987 292 294
49. S. Kanzler, C. Weidemann, G. Gerken, H.F. Lohr, P.R. Galle, K.H. Meyer zum Büschenfelde, and et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis J Hepatol 31 1999 635 640
50. A.J. Czaja, P.T. Donaldson, and A.W. Lohse Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis Am J Gastroenterol 97 2002 413 419
51. K.M. Boberg, R.W. Chapman, G.M. Hirschfield, A.W. Lohse, M.P. Manns, E. Schrumpf, and et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue J Hepatol 54 2011 374 385
52. G.V. Gregorio, B. Portmann, J. Karani, P. Harrison, P.T. Donaldson, D. Vergani, and et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study Hepatology 33 2001 544 553
53. C.P. Rojas, R. Bodicharla, G. Campuzano-Zuluaga, L. Hernandez, and M.M. Rodriguez Autoimmune hepatitis and primary sclerosing cholangitis in children and adolescents Fetal Pediatr Pathol 33 2014 202 209
54. G. Mieli-Vergani, S. Heller, P. Jara, D. Vergani, M.H. Chang, T. Fujisawa, and et al. Autoimmune hepatitis J Pediatr Gastroenterol Nutr 49 2009 158 164
55. N.K. Gatselis, K. Zachou, P. Papamichalis, G.K. Koukoulis, S. Gabeta, G.N. Dalekos, and et al. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? Dig Liver Dis 42 2010 807 812
56. A.W. Lohse, K.H. zum Buschenfelde, B. Franz, S. Kanzler, G. Gerken, and H.P. Dienes Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: evidence for it being a hepatitic form of PBC in genetically susceptible individuals Hepatology 29 1999 1078 1084
57. O. Chazouilleres, D. Wendum, L. Serfaty, S. Montembault, O. Rosmorduc, and R. Poupon Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy Hepatology 28 1998 296 301
58. A. Heurgue, F. Vitry, M.D. Diebold, N. Yaziji, B. Bernard-Chabert, J.L. Pennaforte, and et al. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease Gastroenterol Clin Biol 31 2007 17 25
59. E.M. Kuiper, P.E. Zondervan, and H.R. van Buuren Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome Clin Gastroenterol Hepatol 8 2010 530 534
60. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of cholestatic liver diseases J Hepatol 51 2009 237 267
61. F. Gohlke, A.W. Lohse, H.P. Dienes, H. Lohr, E. Marker-Hermann, G. Gerken, and et al. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis J Hepatol 24 1996 699 705
62. M. Lewin, V. Vilgrain, V. Ozenne, M. Lemoine, D. Wendum, V. Paradis, and et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: a prospective magnetic resonance imaging and histological study Hepatology 50 2009 528 537
63. A.J. Czaja, and H.A. Carpenter Autoimmune hepatitis with incidental histologic features of bile duct injury Hepatology 34 2001 659 665
64. S. Luth, S. Kanzler, C. Frenzel, H.U. Kasper, H.P. Dienes, C. Schramm, and et al. Characteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome J Clin Gastroenterol 43 2009 75 80
65. R. Zenouzi, and A.W. Lohse Long-term outcome in PSC/AIH "overlap syndrome": does immunosuppression also treat the PSC component? J Hepatol 61 2014 1189 1191
66. H. Chung, T. Watanabe, M. Kudo, O. Maenishi, Y. Wakatsuki, and T. Chiba Identification and characterization of IgG4-associated autoimmune hepatitis Liver Int 30 2010 222 231
67. T. Umemura, Y. Zen, H. Hamano, S. Joshita, T. Ichijo, K. Yoshizawa, and et al. Clinical significance of immunoglobulin G4-associated autoimmune hepatitis J Gastroenterol 46 2011 48 55
68. P.J. Trivedi, and G.M. Hirschfield Review article: overlap syndromes and autoimmune liver disease Aliment Pharmacol Ther 36 2012 517 533
69. A. Castiella, E. Zapata, M.I. Lucena, and R.J. Andrade Drug-induced autoimmune liver disease: a diagnostic dilemma of an increasingly reported disease World J Hepatol 6 2014 160 168
70. C. Weiler-Normann, and C. Schramm Drug induced liver injury and its relationship to autoimmune hepatitis J Hepatol 55 2011 747 749
71. P. Beaune, P.M. Dansette, D. Mansuy, L. Kiffel, M. Finck, C. Amar, and et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug Proc Natl Acad Sci U S A 84 1987 551 555
72. M. Bourdi, D. Larrey, J. Nataf, J. Bernuau, D. Pessayre, M. Iwasaki, and et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis J Clin Invest 85 1990 1967 1973
73. S. Appleyard, R. Saraswati, and D.A. Gorard Autoimmune hepatitis triggered by nitrofurantoin: a case series J Med Case Rep 4 2010 311
74. E. Bjornsson, J. Talwalkar, S. Treeprasertsuk, P.S. Kamath, N. Takahashi, S. Sanderson, and et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis Hepatology 51 2010 2040 2048
75. A. Suzuki, E.M. Brunt, D.E. Kleiner, R. Miquel, T.C. Smyrk, R.J. Andrade, and et al. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury Hepatology 54 2011 931 939
76. R.J. Fontana, L.B. Seeff, R.J. Andrade, E. Bjornsson, C.P. Day, J. Serrano, and et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Hepatology 52 2010 730 742
77. A. Heurgué, B. Bernard-Chabert, M. Diebold, F. Vitry, H. Louvet, and P. Geoffroy Drug-induced autoimmune hepatitis: a frequent disorder Gut 56 2007 A271
78. N. Chalasani, R.J. Fontana, H.L. Bonkovsky, P.B. Watkins, T. Davern, J. Serrano, and et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States Gastroenterology 135 2008 1924 1934 1934, e1921-e1924
79. E. Buchel, W. Van Steenbergen, F. Nevens, and J. Fevery Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery Am J Gastroenterol 97 2002 3160 3165
80. D. Samuel, S. Riordan, S. Strasser, J. Kurtovic, I. Singh-Grewel, and D. Koorey Severe autoimmune hepatitis first presenting in the early post partum period Clin Gastroenterol Hepatol 2 2004 622 624
81. R.H. Westbrook, A.D. Yeoman, S. Kriese, and M.A. Heneghan Outcomes of pregnancy in women with autoimmune hepatitis J Autoimmun 38 2012 J239 J244
82. M.A. Heneghan, S.M. Norris, J.G. O'Grady, P.M. Harrison, and I.G. McFarlane Management and outcome of pregnancy in autoimmune hepatitis Gut 48 2001 97 102
83. P. Muratori, S. Loffreda, L. Muratori, R. Ferrari, K. Afandi, F. Cassani, and et al. Spontaneous remission of autoimmune hepatitis during pregnancy Dig Liver Dis 34 2002 608 609
84. D.R. Terrabuio, C.P. Abrantes-Lemos, F.J. Carrilho, and E.L. Cancado Follow-up of pregnant women with autoimmune hepatitis: the disease behavior along with maternal and fetal outcomes J Clin Gastroenterol 43 2009 350 356
85. S. Vento, and F. Cainelli Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev 3 2004 61 69
86. A. Zellos, V. Spoulou, E. Roma-Giannikou, O. Karentzou, G.N. Dalekos, and M. Theodoridou Autoimmune hepatitis type-2 and Epstein-Barr virus infection in a toddler: art of facts or an artifact? Ann Hepatol 12 2013 147 151
87. G.N. Dalekos, H. Wedemeyer, P. Obermayer-Straub, A. Kayser, A. Barut, H. Frank, and et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment J Hepatol 30 1999 366 375
88. L. Muratori, M. Lenzi, M. Cataleta, F. Giostra, F. Cassani, G. Ballardini, and et al. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C J Hepatol 21 1994 199 203
89. S. Vento, F. Cainelli, C. Renzini, and E. Concia Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance Lancet 350 1997 1298 1299
90. G. Mieli-Vergani, and D. Vergani De novo autoimmune hepatitis after liver transplantation J Hepatol 40 2004 3 7
91. A.J. Montano-Loza, F. Vargas-Vorackova, M. Ma, V.G. Bain, K. Burak, T. Kumar, and et al. Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation Liver Int 32 2012 1426 1433
92. M.I. Fiel, and T.D. Schiano Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation Curr Opin Organ Transplant 17 2012 287 292
93. E.I. Rigopoulou, G. Dalekos, and D.P. Bogdanos How common are connective tissue disorders in patients with autoimmune hepatitis? Semin Arthritis Rheum 36 2007 332 [author reply 333]
94. F. Panetta, V. Nobili, M.R. Sartorelli, R.E. Papa, F. Ferretti, A. Alterio, and et al. Celiac disease in pediatric patients with autoimmune hepatitis: etiology, diagnosis, and management Paediatr Drugs 14 2012 35 41
95. A. Teufel, A. Weinmann, G.J. Kahaly, C. Centner, A. Piendl, M. Worns, and et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis J Clin Gastroenterol 44 2010 208 213
96. P. Obermayer-Straub, J. Perheentupa, S. Braun, A. Kayser, A. Barut, S. Loges, and et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy Gastroenterology 121 2001 668 677
97. A. Teufel, A. Weinmann, C. Centner, A. Piendl, A.W. Lohse, P.R. Galle, and et al. Hepatocellular carcinoma in patients with autoimmune hepatitis World J Gastroenterol 15 2009 578 582
98. A.D. Yeoman, T. Al-Chalabi, J.B. Karani, A. Quaglia, J. Devlin, G. Mieli-Vergani, and et al. Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: implications for follow-up and screening Hepatology 48 2008 863 870
99. J.H. Ngu, R.B. Gearry, C.M. Frampton, and C.A. Stedman Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand Hepatology 55 2012 522 529
100. K. Migita, Y. Watanabe, Y. Jiuchi, Y. Nakamura, A. Saito, M. Yagura, and et al. Hepatocellular carcinoma and survival in patients with autoimmune hepatitis (Japanese National Hospital Organization-autoimmune hepatitis prospective study) Liver Int 32 2012 837 844
101. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis Am J Gastroenterol 103 2008 1944 1951
102. T. Hino-Arinaga, T. Ide, R. Kuromatsu, I. Miyajima, K. Ogata, R. Kuwahara, and et al. Risk factors for hepatocellular carcinoma in Japanese patients with autoimmune hepatitis type 1 J Gastroenterol 47 2012 569 576
103. A.J. Czaja Hepatocellular carcinoma and other malignancies in autoimmune hepatitis Dig Dis Sci 58 2013 1459 1476
104. T. Al-Chalabi, J.A. Underhill, B.C. Portmann, I.G. McFarlane, and M.A. Heneghan Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis J Hepatol 48 2008 140 147
105. A. Floreani, G. Niro, E. Rosa Rizzotto, S. Antoniazzi, F. Ferrara, I. Carderi, and et al. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study Aliment Pharmacol Ther 24 2006 1051 1057
106. K. Fujiwara, Y. Fukuda, and O. Yokosuka Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis J Gastroenterol 43 2008 951 958
107. S. Yasui, K. Fujiwara, Y. Yonemitsu, S. Oda, M. Nakano, and O. Yokosuka Clinicopathological features of severe and fulminant forms of autoimmune hepatitis J Gastroenterol 46 2011 378 390
108. S. Luth, J. Herkel, S. Kanzler, C. Frenzel, P.R. Galle, H.P. Dienes, and et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis J Clin Gastroenterol 42 2008 926 930
109. S.P. Georgiadou, K. Zachou, C. Liaskos, S. Gabeta, E.I. Rigopoulou, and G.N. Dalekos Occult hepatitis B virus infection in patients with autoimmune liver diseases Liver Int 29 2009 434 442
110. A. Azhar, M.A. Niazi, K. Tufail, A.H. Malek, M. Balasubramanian, and V. Araya A new approach for treatment of hepatitis C in hepatitis C-autoimmune hepatitis overlap syndrome Gastroenterol Hepatol (N Y) 6 2010 233 236
111. E.I. Rigopoulou, K. Zachou, N. Gatselis, G.K. Koukoulis, and G.N. Dalekos Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome Ann Hepatol 13 2013 127 135
112. D. Vergani, F. Alvarez, F.B. Bianchi, E.L. Cancado, I.R. Mackay, M.P. Manns, and et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group J Hepatol 41 2004 677 683
113. D.P. Bogdanos, P. Invernizzi, I.R. Mackay, and D. Vergani Autoimmune liver serology: current diagnostic and clinical challenges World J Gastroenterol 14 2008 3374 3387
114. A.J. Czaja, and H.A. Homburger Autoantibodies in liver disease Gastroenterology 120 2001 239 249
115. C. Frenzel, J. Herkel, S. Luth, P.R. Galle, C. Schramm, and A.W. Lohse Evaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis Am J Gastroenterol 101 2006 2731 2736
116. D. Villalta, N. Bizzaro, M. Da Re, R. Tozzoli, L. Komorowski, and E. Tonutti Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders Autoimmunity 41 2008 105 110
117. A. Granito, L. Muratori, P. Muratori, G. Pappas, M. Guidi, F. Cassani, and et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis J Clin Pathol 59 2006 280 284
118. C. Liaskos, D.P. Bogdanos, E.T. Davies, and G.N. Dalekos Diagnostic relevance of anti-filamentous actin antibodies in autoimmune hepatitis J Clin Pathol 60 2007 107 108
119. F. Cassani, M. Cataleta, P. Valentini, P. Muratori, F. Giostra, R. Francesconi, and et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile Hepatology 26 1997 561 566
120. F. Bortolotti, P. Vajro, F. Balli, R. Giacchino, C. Crivellaro, C. Barbera, and et al. Non-organ specific autoantibodies in children with chronic hepatitis C J Hepatol 25 1996 614 620
121. M. Lenzi, P. Manotti, L. Muratori, M. Cataleta, G. Ballardini, F. Cassani, and et al. Liver cytosolic 1 antigen-antibody system in type 2 autoimmune hepatitis and hepatitis C virus infection Gut 36 1995 749 754
122. G.N. Dalekos, E. Makri, S. Loges, P. Obermayer-Straub, K. Zachou, T. Tsikrikas, and et al. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece Eur J Gastroenterol Hepatol 14 2002 35 42
123. S. Ferri, L. Muratori, C. Quarneti, P. Muratori, R. Menichella, G. Pappas, and et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C J Hepatol 50 2009 1093 1101
124. N. Kerkar, K. Choudhuri, Y. Ma, A. Mahmoud, D.P. Bogdanos, L. Muratori, and et al. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease J Immunol 170 2003 1481 1489
125. A.W. Lohse, P. Obermayer-Straub, G. Gerken, S. Brunner, U. Altes, H.P. Dienes, and et al. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease - Possible association with a steroid-resistant transplant rejection episode J Hepatol 31 1999 149 155
126. I. Wies, S. Brunner, J. Henninger, J. Herkel, S. Kanzler, K.H. Meyer zum Buschenfelde, and et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis Lancet 355 2000 1510 1515
127. S. Palioura, R.L. Sherrer, T.A. Steitz, D. Soll, and M. Simonovic The human SepSecS-tRNASec complex reveals the mechanism of selenocysteine formation Science 325 2009 321 325
128. M. Baeres, J. Herkel, A.J. Czaja, I. Wies, S. Kanzler, E.L. Cancado, and et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics Gut 51 2002 259 264
129. K. Zachou, S. Gampeta, N.K. Gatselis, K. Oikonomou, J. Goulis, M.N. Manoussakis, and et al. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis Liver Int 35 2015 660 672
130. C. Liaskos, P.P. Bogdanos, E.I. Rigopoulou, G.L. Norman, Z. Shurns, T. Al-Chalabi, and et al. Antibody responses specific for soluble liver antigen co-occur with RO-52 autoantibodies in patients with autoimmune hepatitis J Hepatol 46 2007 S250
131. V. Eyraud, O. Chazouilleres, E. Ballot, C. Corpechot, R. Poupon, and C. Johanet Significance of antibodies to soluble liver antigen/liver pancreas: a large French study Liver Int 29 2009 857 864
132. A.J. Montano-Loza, Z. Shums, G.L. Norman, and A.J. Czaja Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis Liver Int 32 2012 85 92
133. Y. Ma, M. Okamoto, M.G. Thomas, D.P. Bogdanos, A.R. Lopes, B. Portmann, and et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease Hepatology 35 2002 658 664
134. A.J. Czaja, Z. Shums, and G.L. Norman Nonstandard antibodies as prognostic markers in autoimmune hepatitis Autoimmunity 37 2004 195 201
135. S.R. Targan, C. Landers, A. Vidrich, and A.J. Czaja High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis Gastroenterology 108 1995 1159 1166
136. D. Zauli, S. Ghetti, A. Grassi, C. Descovich, F. Cassani, G. Ballardini, and et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis Hepatology 25 1997 1105 1107
137. B. Terjung, U. Spengler, T. Sauerbruch, and H.J. Worman "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines Gastroenterology 119 2000 310 322
138. B. Terjung, H.J. Worman, V. Herzog, T. Sauerbruch, and U. Spengler Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy Clin Exp Immunol 126 2001 37 46
139. C. O'Brien, S. Joshi, J.J. Feld, M. Guindi, H.P. Dienes, and E.J. Heathcote Long-term follow-up of antimitochondrial antibody-positive autoimmune hepatitis Hepatology 48 2008 550 556
140. A.Q. Farias, L.L. Goncalves, P.L. Bittencourt, E.S. De Melo, C.P. Abrantes-Lemos, G. Porta, and et al. Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis J Gastroenterol Hepatol 21 2006 887 893
141. N. Kerkar, Y. Ma, E.T. Davies, P. Cheeseman, G. Mieli-Vergani, and D. Vergani Detection of liver kidney microsomal type 1 antibody using molecularly based immunoassays J Clin Pathol 55 2002 906 909
142. D.J. Gassert, H. Garcia, K. Tanaka, and J.F. Reinus Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis Dig Dis Sci 52 2007 2433 2437
143. A. Potthoff, K. Deterding, C. Trautwein, P. Flemming, C.P. Strassburg, M.P. Manns, and et al. Steroid treatment for severe acute cryptogenic hepatitis Z Gastroenterol 45 2007 15 19
144. A.J. Czaja Behavior and significance of autoantibodies in type 1 autoimmune hepatitis J Hepatol 30 1999 394 401
145. G.V. Gregorio, B. McFarlane, P. Bracken, D. Vergani, and G. Mieli-Vergani Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease Autoimmunity 35 2002 515 519
146. L. Muratori, M. Cataleta, P. Muratori, M. Lenzi, and F.B. Bianchi Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis Gut 42 1998 721 726
147. U. Denzer, A. Arnoldy, S. Kanzler, P.R. Galle, H.P. Dienes, and A.W. Lohse Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications J Clin Gastroenterol 41 2007 103 110
148. U. Denzer, I. Helmreich-Becker, P.R. Galle, and A.W. Lohse Liver assessment and biopsy in patients with marked coagulopathy: value of mini-laparoscopy and control of bleeding Am J Gastroenterol 98 2003 893 900
149. I. Helmreich-Becker, K.H. Meyer zum Buschenfelde, and A.W. Lohse Safety and feasibility of a new minimally invasive diagnostic laparoscopy technique Endoscopy 30 1998 756 762
150. A.J. Czaja, and H.A. Carpenter Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis Gastroenterology 105 1993 1824 1832
151. A.J. Czaja, and H.A. Carpenter Optimizing diagnosis from the medical liver biopsy Clin Gastroenterol Hepatol 5 2007 898 907
152. V.J. Desmet, M. Gerber, J.H. Hoofnagle, M. Manns, and P.J. Scheuer Classification of chronic hepatitis: diagnosis, grading and staging Hepatology 19 1994 1513 1520
153. H.P. Dienes, H. Erberich, V. Dries, P. Schirmacher, and A. Lohse Autoimmune hepatitis and overlap syndromes Clin Liver Dis 6 2002 349 362 vi
154. W.R. Kessler, O.W. Cummings, G. Eckert, N. Chalasani, L. Lumeng, and P.Y. Kwo Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis Clin Gastroenterol Hepatol 2 2004 625 631
155. L.J. Burgart, K.P. Batts, J. Ludwig, G.A. Nikias, and A.J. Czaja Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations Am J Surg Pathol 19 1995 699 708
156. H. Hofer, C. Oesterreicher, F. Wrba, P. Ferenci, and E. Penner Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation J Clin Pathol 59 2006 246 249
157. Y. Zen, K. Notsumata, N. Tanaka, and Y. Nakanuma Hepatic centrilobular zonal necrosis with positive antinuclear antibody: a unique subtype or early disease of autoimmune hepatitis? Hum Pathol 38 2007 1669 1675
158. N. Okano, K. Yamamoto, K. Sakaguchi, Y. Miyake, N. Shimada, T. Hakoda, and et al. Clinicopathological features of acute-onset autoimmune hepatitis Hepatol Res 25 2003 263 270
159. A.J. Czaja, P. Muratori, L. Muratori, H.A. Carpenter, and F.B. Bianchi Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis Liver Int 24 2004 322 329
160. S.W. Schalm, M.G. Korman, W.H. Summerskill, A.J. Czaja, and A.H. Baggenstoss Severe chronic active liver disease. Prognostic significance of initial morphologic patterns Am J Dig Dis 22 1977 973 980
161. I. Helmreich-Becker, and A.W. Lohse Minilaparoskopie in der Leberdiagnostik - ein Vorteil? Z Gastroenterol 39 2001 7 9
162. J. Anastasiou, A. Alisa, S. Virtue, B. Portmann, I. Murray-Lyon, and R. Williams Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy Eur J Gastroenterol Hepatol 22 2010 474 480
163. K. Gutkowski, M. Hartleb, T. Kacperek-Hartleb, M. Kajor, W. Mazur, W. Zych, and et al. Laboratory-based scoring system for prediction of hepatic inflammatory activity in patients with autoimmune hepatitis Liver Int 33 2013 1370 1377
164. M. Kaya, P. Angulo, and K.D. Lindor Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system J Hepatol 33 2000 537 542
165. J.A. Talwalkar, J.C. Keach, P. Angulo, and K.D. Lindor Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system Am J Gastroenterol 97 2002 1191 1197
166. A.J. Czaja Performance parameters of the diagnostic scoring systems for autoimmune hepatitis Hepatology 48 2008 1540 1548
167. A. Czaja, and H.A. Carpenter Validation of scoring system for diagnosis of autoimmune hepatitis Dig Dis Sci 41 1996 305 314
168. D. Qiu, Q. Wang, H. Wang, Q. Xie, G. Zang, H. Jiang, and et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients J Hepatol 54 2011 340 347
169. A.D. Yeoman, R.H. Westbrook, T. Al-Chalabi, I. Carey, N.D. Heaton, B.C. Portmann, and et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease Hepatology 50 2009 538 545
170. M. Neuhauser, E. Bjornsson, S. Treeprasertsuk, F. Enders, M. Silveira, J. Talwalkar, and et al. Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis Am J Gastroenterol 105 2010 345 353
171. P. Muratori, A. Granito, G. Pappas, G.M. Pendino, C. Quarneti, R. Cicola, and et al. The serological profile of the autoimmune hepatitis/primary biliary cirrhosis overlap syndrome Am J Gastroenterol 104 2009 1420 1425
172. A.W. Lohse Recognizing autoimmune hepatitis: scores help, but no more J Hepatol 54 2011 193 194
173. K. Yamamoto, Y. Miyake, H. Ohira, Y. Suzuki, M. Zeniya, M. Onji, and et al. Prognosis of autoimmune hepatitis showing acute presentation Hepatol Res 43 2013 630 638
174. K. Fujiwara, S. Yasui, A. Tawada, Y. Fukuda, M. Nakano, and O. Yokosuka Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group criteria in acute-onset autoimmune hepatitis Liver Int 31 2011 1013 1020
175. G.C. Cook, R. Mulligan, and S. Sherlock Controlled prospective trial of corticosteroid therapy in active chronic hepatitis Q J Med 40 1971 159 185
176. R.D. Soloway, W.H. Summerskill, A.H. Baggenstoss, M.G. Geall, G.L. Gitnick, I.R. Elveback, and et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis Gastroenterology 63 1972 820 833
177. I.M. Murray-Lyon, R.B. Stern, and R. Williams Controlled trial of prednisone and azathioprine in active chronic hepatitis Lancet 1 1973 735 737
178. A.P. Kirk, S. Jain, S. Pocock, H.C. Thomas, and S. Sherlock Late results of the Royal Free Hospital prospective controlled trial of prednisolone therapy in hepatitis B surface antigen negative chronic active hepatitis Gut 21 1980 78 83
179. M.M. Lamers, M.G. van Oijen, M. Pronk, and J.P. Drenth Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials J Hepatol 53 2010 191 198
180. J. De Groote, J. Fevery, and L. Lepoutre Long-term follow-up of chronic active hepatitis of moderate severity Gut 19 1978 510 513
181. A.J. Czaja Features and consequences of untreated type 1 autoimmune hepatitis Liver Int 29 2009 816 823
182. J.F. Dufour, M. Zimmermann, and J. Reichen Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare J Hepatol 37 2002 748 752
183. J. Kogan, R. Safadi, Y. Ashur, D. Shouval, and Y. Ilan Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: a study of 68 patients J Clin Gastroenterol 35 2002 75 81
184. J.J. Keating, C.J. O'Brien, A.J. Stellon, B.C. Portmann, R.D. Johnson, P.J. Johnson, and et al. Influence of aetiology, clinical and histological features on survival in chronic active hepatitis: an analysis of 204 patients Q J Med 62 1987 59 66
185. P. Tan, P. Marotta, C. Ghent, and P. Adams Early treatment response predicts the need for liver transplantation in autoimmune hepatitis Liver Int 25 2005 728 733
186. W.H. Summerskill, M.G. Korman, H.V. Ammon, and A.H. Baggenstoss Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared Gut 16 1975 876 883
187. U. Tage-Jensen, P. Schlichting, J. Aldershvile, P. Andersen, O. Dietrichson, F. Hardt, and et al. Azathioprine versus prednisone in non-alcoholic chronic liver disease (CLD). Relation to a serological classification Liver 2 1982 95 103
188. C. Schramm, C. Weiler-Normann, C. Wiegard, S. Hellweg, S. Muller, and A.W. Lohse Treatment response in patients with autoimmune hepatitis Hepatology 52 2010 2247 2248
189. M. Werner, S. Wallerstedt, S. Lindgren, S. Almer, E. Bjornsson, A. Bergquist, and et al. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response Scand J Gastroenterol 45 2010 457 467
190. Y. Miyake, Y. Iwasaki, R. Terada, R. Okamaoto, H. Ikeda, Y. Makino, and et al. Persistent elevation of serum alanine aminotransferase levels leads to poor survival and hepatocellular carcinoma development in type 1 autoimmune hepatitis Aliment Pharmacol Ther 24 2006 1197 1205
191. S. Verma, B. Gunuwan, M. Mendler, S. Govindrajan, and A. Redeker Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy Am J Gastroenterol 99 2004 1510 1516
192. L. Muratori, P. Muratori, G. Lanzoni, S. Ferri, and M. Lenzi Application of the 2010 American Association for the study of liver diseases criteria of remission to a cohort of Italian patients with autoimmune hepatitis Hepatology 52 2010 1857
193. M.P. Manns, M. Woynarowski, W. Kreisel, Y. Lurie, C. Rust, E. Zuckerman, and et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis Gastroenterology 139 2010 1198 1206
194. A. Danielsson, and H. Prytz Oral budesonide for treatment of autoimmune chronic active hepatitis Aliment Pharmacol Ther 8 1994 585 590
195. J. Wiegand, A. Schuler, S. Kanzler, A. Lohse, U. Beuers, W. Kreisel, and et al. Budesonide in previously untreated autoimmune hepatitis Liver Int 25 2005 927 934
196. A. Csepregi, C. Rocken, G. Treiber, and P. Malfertheiner Budesonide induces complete remission in autoimmune hepatitis World J Gastroenterol 12 2006 1362 1366
197. A.J. Czaja, and K.D. Lindor Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis Gastroenterology 119 2000 1312 1316
198. A. Geier, C. Gartung, C.G. Dietrich, H.E. Wasmuth, P. Reinartz, and S. Matern Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC World J Gastroenterol 9 2003 2681 2685
199. C. Efe, E. Ozaslan, T. Kav, T. Purnak, A. Shorbagi, O. Ozkayar, and et al. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome Autoimmun Rev 11 2012 330 334
200. A.J. Czaja Drug choices in autoimmune hepatitis: part A-Steroids Expert Rev Gastroenterol Hepatol 6 2012 603 615
201. A.J. Czaja, K.V. Menon, and H.A. Carpenter Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis Hepatology 35 2002 890 897
202. L. Sanchez-Urdazpal, A.J. Czaja, B. van Hoek, R.A. Krom, and R.H. Wiesner Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis Hepatology 15 1992 215 221
203. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease Hepatology 46 2007 1138 1145
204. A.D. Yeoman, R.H. Westbrook, Y. Zen, P. Maninchedda, B.C. Portmann, J. Devlin, and et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis Hepatology 53 2011 926 934
205. A.J. Czaja, J. Rakela, and J. Ludwig Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis Gastroenterology 95 1988 448 453
206. P. Ichai, J.C. Duclos-Vallee, C. Guettier, S.B. Hamida, T. Antonini, V. Delvart, and et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis Liver Transpl 13 2007 996 1003
207. S.W. Schalm, H.V. Ammon, and W.H. Summerskill Failure of customary treatment in chronic active liver disease: causes and management Ann Clin Res 8 1976 221 227
208. B. Hoeroldt, E. McFarlane, A. Dube, P. Basumani, M. Karajeh, M.J. Campbell, and et al. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center Gastroenterology 140 2011 1980 1989
209. S. Kanzler, G. Gerken, H. Lohr, P.R. Galle, K.H. Meyer zum Buschenfelde, and A.W. Lohse Duration of immunosuppressive therapy in autoimmune hepatitis J Hepatol 34 2001 354 355
210. A.J. Czaja Rapidity of treatment response and outcome in type 1 autoimmune hepatitis J Hepatol 51 2009 161 167
211. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse Am J Gastroenterol 102 2007 1005 1012
212. A.J. Czaja, A.M. Wolf, and A.H. Baggenstoss Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features Gastroenterology 80 1981 687 692
213. J. Hartl, H. Ehlken, C. Weiler-Normann, M. Sebode, B. Kreuels, N. Pannicke, and et al. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis J Hepatol 62 2015 642 646
214. J.E. Hegarty, K.T. Nouri Aria, B. Portmann, A.L. Eddleston, and R. Williams Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis Hepatology 3 1983 685 689
215. A.J. Czaja, J. Ludwig, A.H. Baggenstoss, and A. Wolf Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis N Engl J Med 304 1981 5 9
216. A.J. Czaja, S.J. Beaver, and M.T. Shiels Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis Gastroenterology 92 1987 215 219
217. M.A. Heneghan, and I.G. McFarlane Current and novel immunosuppressive therapy for autoimmune hepatitis Hepatology 35 2002 7 13
218. A.J. Czaja, G.L. Davis, J. Ludwig, and H.F. Taswell Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis Hepatology 4 1984 622 627
219. T. Al-Chalabi, and M.A. Heneghan Remission in autoimmune hepatitis: what is it, and can it ever be achieved? Am J Gastroenterol 102 2007 1013 1015
220. A.J. Montano-Loza, H.A. Carpenter, and A.J. Czaja Consequences of treatment withdrawal in type 1 autoimmune hepatitis Liver Int 27 2007 507 515
221. A.J. Stellon, J.J. Keating, P.J. Johnson, I.G. McFarlane, and R. Williams Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal Hepatology 8 1988 781 784
222. P.J. Johnson, I.G. McFarlane, and R. Williams Azathioprine for long-term maintenance of remission in autoimmune hepatitis N Engl J Med 333 1995 958 963
223. K.H. Meyer zum Buschenfelde, and A.W. Lohse Autoimmune hepatitis N Engl J Med 333 1995 1004 1005
224. G.L. Chan, G.R. Erdmann, S.A. Gruber, A.J. Matas, and D.M. Canafax Azathioprine metabolism: pharmacokinetics of 6-mercaptopurine, 6-thiouric acid and 6-thioguanine nucleotides in renal transplant patients J Clin Pharmacol 30 1990 358 363
225. L. Lennard The clinical pharmacology of 6-mercaptopurine Eur J Clin Pharmacol 43 1992 329 339
226. M.C. Dubinsky Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety Clin Gastroenterol Hepatol 2 2004 731 743
227. A.C. Allison Immunosuppressive drugs: the first 50 years and a glance forward Immunopharmacology 47 2000 63 83
228. Z. Ben Ari, A. Mehta, L. Lennard, and A.K. Burroughs Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis J Hepatol 23 1995 351 354
229. C. Cuffari, T. Dassopoulos, L. Turnbough, R.E. Thompson, and T.M. Bayless Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease Clin Gastroenterol Hepatol 2 2004 410 417
230. P.G. Langley, J. Underhill, J.M. Tredger, S. Norris, and I.G. McFarlane Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis J Hepatol 37 2002 441 447
231. M.A. Heneghan, M.L. Allan, J.D. Bornstein, A.J. Muir, and D.A. Tendler Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis J Hepatol 45 2006 584 591
232. A.J. Czaja Review article: the management of autoimmune hepatitis beyond consensus guidelines Aliment Pharmacol Ther 38 2013 343 364
233. A.J. Czaja, and H.A. Carpenter Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis Dig Dis Sci 51 2006 968 975
234. D. Otterness, C. Szumlanski, L. Lennard, B. Klemetsdal, J. Aarbakke, J.O. Park-Hah, and et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms Clin Pharmacol Ther 62 1997 60 73
235. B.A. Kaskas, E. Louis, U. Hindorf, E. Schaeffeler, J. Deflandre, F. Graepler, and et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine Gut 52 2003 140 142
236. C.L. Szumlanski, R. Honchel, M.C. Scott, and R.M. Weinshilboum Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes Pharmacogenetics 2 1992 148 159
237. U. Hindorf, K. Jahed, A. Bergquist, H. Verbaan, H. Prytz, S. Wallerstedt, and et al. Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis J Hepatol 52 2010 106 111
238. C. Schramm, J. Herkel, U. Beuers, S. Kanzler, P.R. Galle, and A.W. Lohse Pregnancy in autoimmune hepatitis: outcome and risk factors Am J Gastroenterol 101 2006 556 560
239. M. Werner, E. Bjornsson, H. Prytz, S. Lindgren, S. Almer, U. Broome, and et al. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 42 2007 986 991
240. A. Francella, A. Dyan, C. Bodian, P. Rubin, M. Chapman, and D.H. Present The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study Gastroenterology 124 2003 9 17
241. M. Akbari, S. Shah, F.S. Velayos, U. Mahadevan, and A.S. Cheifetz Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease Inflamm Bowel Dis 19 2013 15 22
242. R. Adamowicz, E. Trzeciak-Supel, R. Smolarczyk, M. Przybylkowska, and S. Marianowska Subsequent pregnancy (twin) in woman with autoimmunological hepatitis Ginekol Pol 76 2005 742 746
243. V. Christopher, T. Al-Chalabi, P.D. Richardson, P. Muiesan, M. Rela, N.D. Heaton, and et al. Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients Liver Transpl 12 2006 1138 1143
244. J.G. Rosenkrantz, J.H. Githens, S.M. Cox, and D.L. Kellum Azathioprine (Imuran) and pregnancy Am J Obstet Gynecol 97 1967 387 394
245. O. Mohamed-Ahmed, C. Nelson-Piercy, K. Bramham, H. Gao, J.J. Kurinczuk, P. Brocklehurst, and et al. Pregnancy outcomes in liver and cardiothoracic transplant recipients: a UK national cohort study PLoS One 9 2014 e89151
246. S. Angelberger, W. Reinisch, A. Messerschmidt, W. Miehsler, G. Novacek, H. Vogelsang, and et al. Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding J Crohns Colitis 5 2011 95 100
247. L.A. Christensen, J.F. Dahlerup, M.J. Nielsen, J.F. Fallingborg, and K. Schmiegelow Azathioprine treatment during lactation Aliment Pharmacol Ther 28 2008 1209 1213
248. G.V. Gregorio, B. Portmann, F. Reid, P.T. Donaldson, D.G. Doherty, M. McCartney, and et al. Autoimmune hepatitis in childhood: a 20-year experience Hepatology 25 1997 541 547
249. A.J. Czaja, H.A. Carpenter, P.J. Santrach, and S.B. Moore Significance of HLA DR4 in type 1 autoimmune hepatitis Gastroenterology 105 1993 1502 1507
250. G. Maggiore, O. Bernard, M. Hadchouel, P. Hadchouel, M. Odievre, and D. Alagille Treatment of autoimmune chronic active hepatitis in childhood J Pediatr 104 1984 839 844
251. G. Maggiore, F. Veber, O. Bernard, M. Hadchouel, J.C. Homberg, F. Alvarez, and et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents J Pediatr Gastroenterol Nutr 17 1993 376 381
252. S. Banerjee, R. Rahhal, and W.P. Bishop Azathioprine monotherapy for maintenance of remission in pediatric patients with autoimmune hepatitis J Pediatr Gastroenterol Nutr 43 2006 353 356
253. M.M. Aw, A. Dhawan, M. Samyn, A. Bargiota, and G. Mieli-Vergani Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up J Hepatol 51 2009 156 160
254. D. Debray, G. Maggiore, J.P. Girardet, E. Mallet, and O. Bernard Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis J Pediatr 135 1999 111 114
255. F. Alvarez, M. Ciocca, C. Canero-Velasco, M. Ramonet, M.T. de Davila, M. Cuarterolo, and et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children J Hepatol 30 1999 222 227
256. R. Malekzadeh, S. Nasseri-Moghaddam, M.J. Kaviani, H. Taheri, N. Kamalian, and M. Sotoudeh Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis Dig Dis Sci 46 2001 1321 1327
257. M. Cuarterolo, M. Ciocca, C.C. Velasco, M. Ramonet, T. Gonzalez, S. Lopez, and et al. Follow-up of children with autoimmune hepatitis treated with cyclosporine J Pediatr Gastroenterol Nutr 43 2006 635 639
258. M. Woynarowski, A. Nemeth, Y. Baruch, S. Koletzko, M. Melter, B. Rodeck, and et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents J Pediatr 163 2013 e1
259. M.A. Worns, A. Teufel, S. Kanzler, A. Shrestha, A. Victor, G. Otto, and et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases Am J Gastroenterol 103 2008 138 146
260. A.J. Czaja, and H.A. Carpenter Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly Hepatology 43 2006 532 538
261. Y. Miyake, Y. Iwasaki, A. Takaki, H. Kobashi, K. Sakaguchi, and Y. Shiratori Clinical features of Japanese elderly patients with type 1 autoimmune hepatitis Intern Med 46 2007 1945 1949
262. A. Granito, L. Muratori, G. Pappas, P. Muratori, S. Ferri, F. Cassani, and et al. Clinical features of type 1 autoimmune hepatitis in elderly Italian patients Aliment Pharmacol Ther 21 2005 1273 1277
263. K. Ishak, A. Baptista, L. Bianchi, F. Callea, J. De Groote, F. Gudat, and et al. Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
264. J.Y. Reginster, and N. Burlet Osteoporosis: a still increasing prevalence Bone 38 2006 S4 S9
265. F. De Vries, M. Bracke, H.G. Leufkens, J.W. Lammers, C. Cooper, and T.P. Van Staa Fracture risk with intermittent high-dose oral glucocorticoid therapy Arthritis Rheum 56 2007 208 214
266. J.R. Curtis, and K.G. Saag Prevention and treatment of glucocorticoid-induced osteoporosis Curr Osteoporos Rep 5 2007 14 21
267. American Gastroenterological Association American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders Gastroenterology 125 2003 937 940
268. A. Kornbluth, M. Hayes, S. Feldman, M. Hunt, E. Fried-Boxt, S. Lichtiger, and et al. Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria Am J Gastroenterol 101 2006 1546 1550
269. M.D. Long, M.T. Thiny, R.S. Sandler, and L.M. Gangarosa Bone health in a tertiary-care gastroenterology and hepatology population Dig Dis Sci 55 2010 2263 2269
270. J. Collier Bone disorders in chronic liver disease Hepatology 46 2007 1271 1278
271. A. Pares, and N. Guanabens Treatment of bone disorders in liver disease J Hepatol 45 2006 445 453
272. A.D. Yeoman, R.H. Westbrook, Y. Zen, W. Bernal, T. Al-Chalabi, J.A. Wendon, and et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome J Hepatol 61 2014 876 882
273. S. Verma, A. Maheshwari, and P. Thuluvath Liver failure as initial presentation of autoimmune hepatitis: clinical characteristics, predictors of response to steroid therapy, and outcomes Hepatology 49 2009 1396 1397
274. J.R. Potts, and S. Verma Optimizing management in autoimmune hepatitis with liver failure at initial presentation World J Gastroenterol 17 2011 2070 2075
275. C. Weiler-Normann, and A.W. Lohse Acute autoimmune hepatitis: many open questions J Hepatol 61 2014 727 729
276. C. Rumbo, K.M. Emerick, S. Emre, and B.L. Shneider Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report J Pediatr Gastroenterol Nutr 35 2002 391 398
277. B. Wusk, G.A. Kullak-Ublick, C. Rammert, A. von Eckardstein, M. Fried, and K.M. Rentsch Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis Eur J Gastroenterol Hepatol 16 2004 1407 1413
278. H.K. Dhaliwal, R. Anderson, E.L. Thornhill, S. Schneider, E. McFarlane, D. Gleeson, and et al. Clinical significance of azathioprine metabolites for the maintenance of remission in autoimmune hepatitis Hepatology 56 2012 1401 1408
279. A.W. Lohse, and H. Gil Reactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment J Hepatol 54 2011 837 839
280. V. Selvarajah, A.J. Montano-Loza, and A.J. Czaja Systematic review: managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs Aliment Pharmacol Ther 36 2012 691 707
281. A.D. Yeoman, M.S. Longhi, and M.A. Heneghan Review article: the modern management of autoimmune hepatitis Aliment Pharmacol Ther 31 2010 771 787
282. J.T. Hlivko, M.L. Shiffman, R.T. Stravitz, V.A. Luketic, A.J. Sanyal, M. Fuchs, and et al. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis Clin Gastroenterol Hepatol 6 2008 1036 1040
283. E.M. Hennes, Y.H. Oo, C. Schramm, U. Denzer, P. Buggisch, C. Wiegard, and et al. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 103 2008 3063 3070
284. K. Sharzehi, M.A. Huang, I.R. Schreibman, and K.A. Brown Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy Can J Gastroenterol 24 2010 588 592
285. M. Sciveres, S. Caprai, G. Palla, C. Ughi, and G. Maggiore Effectiveness and safety of ciclosporin as therapy for autoimmune diseases of the liver in children and adolescents Aliment Pharmacol Ther 19 2004 209 217
286. K.E. Sherman, M. Narkewicz, and P.C. Pinto Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis J Hepatol 21 1994 1040 1047
287. N.F. Fernandes, A.G. Redeker, J.M. Vierling, F.G. Villamil, and T.L. Fong Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis Am J Gastroenterol 94 1999 241 248
288. B.A. Aqel, V. Machicao, B. Rosser, R. Satyanarayana, D.M. Harnois, and R.C. Dickson Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis J Clin Gastroenterol 38 2004 805 809
289. F.S. Larsen, B. Vainer, M. Eefsen, P.N. Bjerring, and B. Adel Hansen Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis World J Gastroenterol 13 2007 3232 3236
290. M.M. Tannous, J. Cheng, K. Muniyappa, I. Farooq, A. Bharara, M. Kappus, and et al. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience Aliment Pharmacol Ther 34 2011 405 407
291. S. Kanzler, G. Gerken, H.P. Dienes, K.H. Meyer zum Buschenfelde, and A.W. Lohse Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases Z Gastroenterol 35 1997 571 578
292. K.W. Burak, S.J. Urbanski, and M.G. Swain Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate J Hepatol 29 1998 990 993
293. K.W. Burak, M.G. Swain, T. Santodomingo-Garzon, S.S. Lee, S.J. Urbanski, A.I. Aspinall, and et al. Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy Can J Gastroenterol 27 2013 273 280
294. C. Weiler-Normann, C. Schramm, A. Quaas, C. Wiegard, C. Glaubke, N. Pannicke, and et al. Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis J Hepatol 58 2013 529 534
295. M.A. Borman, S. Urbanski, and M.G. Swain Anti-TNF-induced autoimmune hepatitis J Hepatol 61 2014 169 170
296. C. Weiler-Normann, J. Herkel, C. Schramm, and A.W. Lohse Reply to: "anti-TNF-induced autoimmune hepatitis" J Hepatol 61 2014 170 171
297. N. Kerkar, C. Dugan, C. Rumbo, R.A. Morotti, G. Gondolesi, B.L. Shneider, and et al. Rapamycin successfully treats post-transplant autoimmune hepatitis Am J Transplant 5 2005 1085 1089
298. H. Chatrath, L. Allen, and T.D. Boyer Use of sirolimus in the treatment of refractory autoimmune hepatitis Am J Med 127 2014 1128 1131
299. A. Floreani, R. Liberal, D. Vergani, and G. Mieli-Vergani Autoimmune hepatitis: contrasts and comparisons in children and adults - A comprehensive review J Autoimmun 46 2013 7 16
300. N. Kerkar, R.A. Annunziato, L. Foley, J. Schmeidler, C. Rumbo, S. Emre, and et al. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem J Pediatr Gastroenterol Nutr 43 2006 629 634
301. C. Soanes, and S. Timmons Improving transition: a qualitative study examining the attitudes of young people with chronic illness transferring to adult care J Child Health Care 8 2004 102 112
302. D. Kelly Theory to reality: the role of the transition nurse coordinator Br J Nurs 23 2014 888 894
303. D.S. Pratt, D.P. Flavin, and M.M. Kaplan The successful treatment of autoimmune hepatitis with 6-mercaptopurine after failure with azathioprine Gastroenterology 110 1996 271 274
304. O. Chazouilleres, D. Wendum, L. Serfaty, O. Rosmorduc, and R. Poupon Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome J Hepatol 44 2006 400 406
305. S. Joshi, K. Cauch-Dudek, I.R. Wanless, K.D. Lindor, R. Jorgensen, K. Batts, and et al. Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid Hepatology 35 2002 409 413
306. C. Rust, and U. Beuers Overlap syndromes among autoimmune liver diseases World J Gastroenterol 14 2008 3368 3373
307. E. Ozaslan, C. Efe, A. Heurgue-Berlot, T. Kav, C. Masi, T. Purnak, and et al. Factors associated with response to therapy and outcome of patients with primary biliary cirrhosis with features of autoimmune hepatitis Clin Gastroenterol Hepatol 12 2014 863 869
308. R. Poupon, O. Chazouilleres, C. Corpechot, and Y. Chretien Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis Hepatology 44 2006 85 90
309. A. Floreani, E.R. Rizzotto, F. Ferrara, I. Carderi, D. Caroli, L. Blasone, and et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome Am J Gastroenterol 100 2005 1516 1522
310. T. Al-Chalabi, B.C. Portmann, W. Bernal, I.G. McFarlane, and M.A. Heneghan Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival Aliment Pharmacol Ther 28 2008 209 220
311. M. Gautam, R. Cheruvattath, and V. Balan Recurrence of autoimmune liver disease after liver transplantation: a systematic review Liver Transpl 12 2006 1813 1824
312. M. Carbone, and J.M. Neuberger Autoimmune liver disease, autoimmunity and liver transplantation J Hepatol 60 2014 210 223
313. A. Gonzalez-Koch, A.J. Czaja, H.A. Carpenter, S.K. Roberts, M.R. Charlton, M.K. Porayko, and et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation Liver Transpl 7 2001 302 310
314. M. Salcedo, J. Vaquero, R. Banares, M. Rodriguez-Mahou, E. Alvarez, J.L. Vicario, and et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation Hepatology 35 2002 349 356
315. V. Ortiz, M. Berenguer, J.M. Rayon, D. Carrasco, and J. Berenguer Contribution of obesity to hepatitis C-related fibrosis progression Am J Gastroenterol 97 2002 2408 2414
316. B. Liu, A. Balkwill, G. Reeves, and V. Beral Million Women Study C. Body mass index and risk of liver cirrhosis in middle aged UK women: prospective study BMJ 340 2010 c912
317. European Association for the Study of the Liver EASL Clinical Practice Guidelines: management of chronic hepatitis B virus infection J Hepatol 57 2012 167 185
318. J.G. O'Leary, K. Zachary, J. Misdraji, and R.T. Chung De novo autoimmune hepatitis during immune reconstitution in an HIV-infected patient receiving highly active antiretroviral therapy Clin Infect Dis 46 2008 e12 e14
319. Y.A. Puius, L.M. Dove, D.G. Brust, D.P. Shah, and J.H. Lefkowitch Three cases of autoimmune hepatitis in HIV-infected patients J Clin Gastroenterol 42 2008 425 429
320. D.W. Wan, K. Marks, R.K. Yantiss, and A.H. Talal Autoimmune hepatitis in the HIV-infected patient: a therapeutic dilemma AIDS Patient Care STDS 23 2009 407 413
321. J.K. Dyson, G. Webb, G.M. Hirschfield, A. Lohse, U. Beuers, K. Lindor, and et al. Unmet clinical need in autoimmune liver diseases J Hepatol 62 2015 208 218
322. V. Héon-Klin, A. Halbach, M. Schlangen, and B. Schnieders Developing a national plan for rare diseases in Germany through concerted action: the national action league for people with rare diseases Orphanet J Rare Dis 7 2012 A9-A9
323. A. Olauson The Agrenska centre: a socioeconomic case study of rare diseases Pharmacoeconomics 20 2002 73 75
324. L.A. Fogarty, B.A. Curbow, J.R. Wingard, K. McDonnell, and M.R. Somerfield Can 40 seconds of compassion reduce patient anxiety? J Clin Oncol 17 1999 371 379
325. J.A. Talwalkar, and W.R. Kim Medical and economic impact of autoimmune hepatitis Clin Liver Dis 6 2002 649 667
326. S.M. van der Plas, B.E. Hansen, J.B. de Boer, T. Stijnen, J. Passchier, R.A. de Man, and et al. Generic and disease-specific health related quality of life of liver patients with various aetiologies: a survey Qual Life Res 16 2007 375 388
327. R. Gulati, K.R. Radhakrishnan, V. Hupertz, R. Wyllie, N. Alkhouri, S. Worley, and et al. Health-related quality of life in children with autoimmune liver disease J Pediatr Gastroenterol Nutr 57 2013 444 450